Putnam Investments’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $521M | Buy |
3,864,917
+166,655
| +5% | +$21.7M | 0.69% | 48 |
|
|
2023
Q3 | $501M | Sell |
3,698,262
-60,288
| -2% | -$8.23M | 0.76% | 41 |
|
|
2023
Q2 | $538M | Buy |
3,758,550
+24,767
| +0.7% | +$3.64M | 0.79% | 37 |
|
|
2023
Q1 | $518M | Buy |
3,733,783
+12,516
| +0.3% | +$1.68M | 0.83% | 34 |
|
|
2022
Q4 | $505M | Buy |
3,721,267
+50,931
| +1% | +$6.39M | 0.88% | 34 |
|
|
2022
Q3 | $403M | Sell |
3,670,336
-1,093
| -0% | -$139K | 0.77% | 38 |
|
|
2022
Q2 | $485M | Buy |
3,671,429
+13,648
| +0.4% | +$1.79M | 0.87% | 28 |
|
|
2022
Q1 | $485M | Buy |
3,657,781
+98,129
| +3% | +$11.8M | 0.73% | 37 |
|
|
2021
Q4 | $415M | Buy |
3,559,652
+28,516
| +0.8% | +$3.36M | 0.59% | 51 |
|
|
2021
Q3 | $424M | Buy |
3,531,136
+1,177,172
| +50% | +$137M | 0.66% | 44 |
|
|
2021
Q2 | $282M | Buy |
2,353,964
+6,548
| +0.3% | +$718K | 0.44% | 74 |
|
|
2021
Q1 | $233M | Buy |
2,347,416
+105,929
| +5% | +$10.6M | 0.39% | 73 |
|
|
2020
Q4 | $224M | Buy |
2,241,487
+125,820
| +6% | +$13.3M | 0.4% | 75 |
|
|
2020
Q3 | $232M | Buy |
2,115,667
+17,362
| +0.8% | +$1.93M | 0.46% | 61 |
|
|
2020
Q2 | $222M | Sell |
2,098,305
-288,628
| -12% | -$29.8M | 0.47% | 57 |
|
|
2020
Q1 | $213M | Buy |
2,386,933
+39,749
| +2% | +$3.74M | 0.56% | 47 |
|
|
2019
Q4 | $234M | Buy |
2,347,184
+25,940
| +1% | +$2.44M | 0.48% | 57 |
|
|
2019
Q3 | $207M | Buy |
2,321,244
+27,853
| +1% | +$2.42M | 0.46% | 61 |
|
|
2019
Q2 | $189M | Buy |
2,293,391
+2,312
| +0.1% | +$181K | 0.42% | 73 |
|
|
2019
Q1 | $185M | Buy |
2,291,079
+28,636
| +1% | +$2.26M | 0.43% | 73 |
|
|
2018
Q4 | $172M | Buy |
2,262,443
+56,867
| +3% | +$4.44M | 0.45% | 66 |
|
|
2018
Q3 | $175M | Buy |
2,205,576
+13,442
| +0.6% | +$1.02M | 0.38% | 74 |
|
|
2018
Q2 | $154M | Sell |
2,192,134
-5,147
| -0.2% | -$370K | 0.35% | 85 |
|
|
2018
Q1 | $154M | Sell |
2,197,281
-1,397
| -0.1% | -$96.8K | 0.36% | 86 |
|
|
2017
Q4 | $153M | Buy |
2,198,678
+33,150
| +2% | +$2.24M | 0.34% | 86 |
|
|
2017
Q3 | $147M | Sell |
2,165,528
-44,475
| -2% | -$2.81M | 0.34% | 83 |
|
|
2017
Q2 | $151M | Buy |
2,210,003
+52,109
| +2% | +$3.4M | 0.35% | 81 |
|
|
2017
Q1 | $134M | Buy |
2,157,894
+990
| +0% | +$57.6K | 0.32% | 91 |
|
|
2016
Q4 | $118M | Sell |
2,156,904
-26,203
| -1% | -$1.49M | 0.28% | 95 |
|
|
2016
Q3 | $143M | Buy |
2,183,107
+5,984
| +0.3% | +$391K | 0.35% | 77 |
|
|
2016
Q2 | $131M | Buy |
2,177,123
+2,804
| +0.1% | +$163K | 0.32% | 77 |
|
|
2016
Q1 | $122M | Sell |
2,174,319
-45,536
| -2% | -$2.74M | 0.29% | 83 |
|
|
2015
Q4 | $151M | Sell |
2,219,855
-15,847
| -0.7% | -$1.04M | 0.34% | 66 |
|
|
2015
Q3 | $142M | Sell |
2,235,702
-368
| -0% | -$24.2K | 0.32% | 67 |
|
|
2015
Q2 | $142M | Sell |
2,236,070
-139,201
| -6% | -$9.53M | 0.29% | 73 |
|
|
2015
Q1 | $163M | Sell |
2,375,271
-442,777
| -16% | -$30.8M | 0.32% | 72 |
|
|
2014
Q4 | $198M | Buy |
2,818,048
+62,570
| +2% | +$4.48M | 0.41% | 50 |
|
|
2014
Q3 | $197M | Buy |
2,755,478
+433,335
| +19% | +$31.7M | 0.42% | 57 |
|
|
2014
Q2 | $173M | Sell |
2,322,143
-122,631
| -5% | -$8.87M | 0.37% | 69 |
|
|
2014
Q1 | $159M | Buy |
2,444,774
+111,185
| +5% | +$7.18M | 0.36% | 71 |
|
|
2013
Q4 | $139M | Buy |
2,333,589
+133,266
| +6% | +$7.24M | 0.33% | 76 |
|
|
2013
Q3 | $114M | Buy |
2,200,323
+1,695,258
| +336% | +$85.1M | 0.31% | 86 |
|
|
2013
Q2 | $23.9M | Buy |
+505,065
| New | +$25.7M | 0.07% | 267 |
|
Other funds holding AZN
Putnam Investments's AZN Position: Q4 2023 in Review
Putnam Investments increased its AstraZeneca (AZN) stake by 4.5% in Q4 2023, buying an estimated $21.7M and bringing the position to 3,864,917 shares worth $521M. The position accounts for 0.69% of the portfolio, ranked #48.
Putnam Investments first reported a position in AZN in Q2 2013 and has held it in 43 quarters since. The position peaked at $538M in Q2 2023. 1,130 funds tracked by Wall St. Rank hold AZN as of Q4 2023.
- Putnam Investments held 3,864,917 shares of AstraZeneca worth $521M as of Q4 2023.
- Putnam Investments bought 166,655 AstraZeneca shares in Q4 2023, an estimated $21.7M.
- AstraZeneca made up 0.69% of Putnam Investments's portfolio in Q4 2023, its #48 holding.
- Putnam Investments first reported a position in AstraZeneca in Q2 2013 and has held it in 43 quarters since.
- Putnam Investments's AstraZeneca position peaked at $538M in Q2 2023.
- 1,130 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.
Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.